•  
  •  
 

Subject Area

Community Medicine

Article Type

Original Study

Abstract

Objective The objective of this study was to evaluate fibroblast growth factor 23 (FGF23) expression in patients with chronic kidney disease (CKD) and its effect on diagnosis, grading, and prognosis of patients. Background CKD is recognized as a major public health problem in which there is progressive loss in renal function over a period of months or years. FGF23 is a protein that in humans is encoded by the FGF23 gene. FGF23 is a member of the FGF family which is responsible for phosphate metabolism. Patients and methods This study was conducted on 73 patients with CKD (with its five stages) and 15 age-matched and sex-matched healthy individuals as a control group. All patients were subjected to full history taking, clinical examination, and laboratory investigations. FGF23 was measured for all the study participants using enzyme-linked immunosorbent assay technique. Results FGF23 expression increased gradually with increased degree of CKD than in controls. Conclusion There is increased expression of FGF23 in the serum of patients with CKD with its 5°.

Download

Share

COinS